Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

Biologics for severe asthma

Biologic agents target specific aspects of a disease process and so present an opportunity for effective, selective therapy. They can be highly engineered to fine-tune their pharmacologic properties for maximum clinical benefit.1-2

The inflammatory cascade in asthma is a complex process and there may be emphasis on certain pathways depending on the disease subtype. 3-4A variety of monoclonal antibodies against inflammatory cytokines, chemokines or their receptors have reached or are approaching the market.4-5These biologics have the potential to both treat and further define specific severe asthma phenotypes, because they target a specific underlying mechanism of disease.

References:

  1. Chames P, et al. Br J Pharmacol 2009;157:220–33.
  2. Chan AC, Carter PJ. Nat Rev Immunol 2010;10:301–16.
  3. Brusselle GG, et al. Nat Med 2013;19:977–9.
  4. Chung KF, et al. Eur Respir J 2014;43:343–73.
  5. Bice JB, et al. Ann Allergy Asthma Immunol 2014;112:108–15.